Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma

EP: 1.Introduction and Exploring the Financial Burden of Follicular Lymphoma

EP: 2.Optimizing First- and Second-Line Treatment Strategies in Follicular Lymphoma

EP: 3.Advancing Care in Relapsed/Refractory Follicular Lymphoma Beyond Chemotherapy

EP: 4.Integrating Bispecific Antibodies and Evolving Strategies in Relapsed/Refractory Follicular Lymphoma

EP: 5.Implications of the RELEVANCE Study and Optimal Use of R² in Second-Line Follicular Lymphoma

EP: 6.Targeted Therapies and Bispecific Antibodies in Second-Line Follicular Lymphoma

EP: 7.Epcoritamab Maintenance and Quality of Life Considerations in Follicular Lymphoma

EP: 8.Real‑World “Time Toxicity” and Patient Impact: Lessons from ASH 2025 for Epcoritamab in Follicular Lymphoma

Now Viewing

EP: 9.Operational Challenges and Solutions for Implementing Bispecific Antibodies in Follicular Lymphoma

The introduction of bispecific antibodies in follicular lymphoma has created new operational challenges for oncology practices. Common pain points include coordinating frequent infusions, managing extended monitoring for adverse events such as cytokine release syndrome, and ensuring staff are trained in the unique administration protocols. Additionally, scheduling conflicts, resource allocation, and patient education requirements can strain clinic workflows. Overcoming these challenges requires a proactive, multidisciplinary approach. Strategies include establishing standardized protocols for monitoring and toxicity management, leveraging advanced scheduling systems, and providing comprehensive patient and caregiver education. Collaboration between nursing, pharmacy, and physician teams is essential to streamline care and minimize treatment delays. By addressing these operational hurdles, practices can maximize the benefits of bispecific therapies while maintaining patient safety and efficiency, ultimately improving both clinical outcomes and patient experience in follicular lymphoma management.